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Conjugative plasmid transfer presents a serious threat to
human health as the most important means of spreading
antibiotic resistance and virulence genes among bacteria. The
required direct cell–cell contact is established by a multi-
protein complex, the conjugative type IV secretion system
(T4SS). The conjugative core complex spans the cellular
envelope and serves as a channel for macromolecular
secretion. T4SSs of Gram-negative (G) origin have been
studied in great detail. In contrast, T4SSs of Gram-positive
(G+) bacteria have only received little attention thus far,
despite the medical relevance of numerous G+ pathogens
(e.g. enterococci, staphylococci and streptococci). This study
provides structural information on the type IV secretion
(T4S) protein TraK of the G+ broad host range Enterococcus
conjugative plasmid pIP501. The crystal structure of the
N-terminally truncated construct TraK was determined to
3.0 A˚ resolution and exhibits a novel fold. Immunolocalization
demonstrated that the protein localizes to the cell wall facing
towards the cell exterior, but does not exhibit surface
accessibility. Circular dichroism, dynamic light scattering and
size-exclusion chromatography confirmed the protein to be a
monomer. With the exception of proteins from closely related
T4SSs, no significant sequence or structural relatives were
found. This observation marks the protein as a very exclusive,
specialized member of the pIP501 T4SS.
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1. Introduction
Bacterial conjugation is the major contributor to horizontal
gene transfer (Grohmann et al., 2003; Williams & Hergenr-
other, 2008; Zechner et al., 2012). The conjugative spread of
plasmid-encoded antibiotic-resistance and virulence genes
presents a serious threat to human health. The process of
conjugation involves transport of DNA from a donor to a
recipient cell, which requires direct contact between the cells
(Cascales & Christie, 2003; Grohmann et al., 2003; Alvarez-
Martinez & Christie, 2009). The so-called type IV secretion
system (T4SS) is responsible for the transfer. Conjugative
T4SSs are plasmid-encoded, multi-protein complexes that are
large enough to span the bacterial cell wall (Llosa et al., 2002).
A great number of studies have unveiled significant informa-
tion about T4SSs of Gram-negative (G) origin, such as the
F-plasmid-, R388- and pKM101-encoded T4SSs of Escherichia
coli and the Ti-plasmid-encoded T4SS of Agrobacterium
tumefaciens (Llosa et al., 2009; de la Cruz et al., 2010; Hayes et
al., 2010; Reˆgo et al., 2010; Smillie et al., 2010; Wallden et al.,
2010; Thanassi et al., 2012; Zechner et al., 2012; Christie et al.,
2014). In contrast, the great majority of our knowledge on
T4SSs of Gram-positive (G+) origin is based on similarities to
counterparts from G systems (Grohmann et al., 2003; Abajy
et al., 2007; Goessweiner-Mohr, Arends et al., 2013). Never-
theless, a significant amount of information on G+ type IV
secretion (T4S) has become available over the last five years.
According to Chen et al. (2008), the conjugative transfer of the
substrate is initiated by the putative coupling protein PcfC of
the Enterococcus sex-pheromone plasmid pCF10 (Chen et al.,
2008). The protein mediates the NTP-dependent transfer
through a pCF10-encoded T4S channel (Li et al., 2012). The
Rood group has made a substantial contribution to our
understanding of G+ T4S by characterizing the pCW3-
encoded T4SS derived from Clostridium perfringens (Bannam
et al., 2006; Parsons et al., 2007; Teng et al., 2008; Steen et al.,
2009; Bantwal et al., 2012). Li and coworkers reported for the
first time the horizontal transfer of a G+ pathogenicity island,
which was shown to be mediated by a genomic island-type
T4SS, and suggested a hypothetical model for T4S in epidemic
Streptococcus suis strains (Li et al., 2011). Last year, the first
structural information on T4SS proteins of G+ origin finally
became available (Goessweiner-Mohr et al., 2012; Porter et al.,
2012; Wallde´n et al., 2012; Goessweiner-Mohr, Grumet,
Arends et al., 2013; Goessweiner-Mohr, Grumet, Pavkov-
Keller et al., 2013).
The multiple antibiotic-resistance plasmid pIP501 (Horod-
niceanu et al., 1979) isolated from S. agalactiae has the
broadest known host range in G+ bacteria. Furthermore,
Kurenbach and coworkers were able to demonstrate that
pIP501 is the first conjugative plasmid of G+ origin which
stably replicates in G bacteria (Kurenbach et al., 2003). The
pIP501 T4SS operon encodes 15 putative T4SS (Tra) proteins,
of which only four show significant sequence similarity to the
Ti-plasmid-encoded T4SS from A. tumefaciens. The ATPase
TraE (related to VirB4) is most likely to drive the conjugative
process by hydrolyzing ATP. Furthermore, it interacts with
itself and several other potential pIP501 T4SS proteins (Abajy
et al., 2007). The coupling protein TraJ supposedly connects
the macromolecular complex of single-stranded plasmid DNA
and relaxosome proteins with the secretory conduit. The
hexameric protein is related to VirD4; however, it lacks the
transmembrane region typical of other coupling proteins
(Abajy et al., 2007; E. Grohmann et al., unpublished work).
TraJ might be recruited to the cell membrane by the pIP501
T4SS protein TraI (Alvarez-Martinez & Christie, 2009). The
muramidase TraG (related to VirB1) is responsible for locally
opening the thick peptidoglycan layer of G+ bacteria, a
process required for the buildup of the T4SS core complex
(Arends et al., 2013). Furthermore, the pIP501-encoded
relaxase TraA has been studied in detail (Kopec et al., 2005;
Kurenbach et al., 2006). As the first protein of the T4SS
operon, it was shown to bind specifically to the origin of
transfer (oriT) and to auto-regulate the expression of the
pIP501 T4SS components.
Recently, we published the 2.5 A˚ resolution structure of
the C-terminal domain of the pIP501 T4SS protein TraM
(Goessweiner-Mohr, Grumet, Arends et al., 2013). Despite this
first structural data and progress in the functional character-
ization of some key proteins, the structural and functional
characterization of most of the 15 T4SS proteins is still lacking.
Moreover, we still need to identify the key components of the
proposed conjugative core complex, as was performed for the
G model system from E. coli (Fronzes et al., 2009).
Here, we present the biophysical and structural character-
ization of the N-terminally truncated protein TraK (formerly
named ORF11; GenBank CAD44391.1), a 30.6 kDa protein
(His-tagged TraK66–307, further referred to as TraK) encoded
by the Enterococcus faecalis conjugative plasmid pIP501. We
report the 3.0 A˚ resolution structure, which has been solved
by selenomethionine multiwavelength anomalous dispersion
(MAD). The protein localizes to the cell envelope, facing
towards the cell exterior, and behaves as a monomer under the
tested conditions. With the exception of the T4SS proteins of
closely related G+ T4SSs showing high sequence identity, no
significant sequence-based or structure-based relationships
could be found. These results mark TraK as a highly exclusive
T4SS protein that is only found in Enterococcus and Strepto-
coccus T4SSs. Thus, TraK appears to be an interesting target
for further functional studies.
2. Materials and methods
2.1. Expression, purification and buffer optimization
traK was cloned into the 7His-tag expression vector
pQTEV (a gift from K. Bu¨ssow, Max-Planck-Institute for
Molecular Genetics, Berlin, Germany), and E. coli BL21-
CodonPlus(DE3)-RIL (Stratagene, Amsterdam, The Nether-
lands) competent cells were transformed with the recombinant
construct pQTEV-traK. Large-scale expression was
performed in 500 ml LB medium supplemented with
100 mg ml1 ampicillin. TraK expression was induced at an
OD600 of 0.6 by the addition of 1 mM IPTG, and expression
continued for 3 h at 37C. The cells were harvested and
immediately frozen at 20C. TraK expression levels were
monitored by SDS–PAGE.
TraK cell pellets were first lysed in 40 ml 25 mM HEPES
pH 7.6, 75 mM Na2SO4. 2 U of DNAse (Sigma–Aldrich, St
Louis, USA) was added and PMSF and benzamidine were
added to final concentrations of 1 and 2 mM, respectively. The
cell suspension was vigorously mixed (UltraTurrax, IKA,
Staufen, Germany) and kept on ice for 30 min. The suspension
was sonicated (Sonopuls HD2070, Bandelin; 1 min continuous
sonification, 80% amplitude) and centrifuged for 30 min at
8C and 15 000g. Pellet and supernatant fractions were
analyzed by SDS–PAGE. The pellet was applied to a second
extraction step with 20 ml of the above buffer. The TraK-
containing supernatant fractions were pooled and loaded onto
a HisTrap FF 1 ml column (GE Healthcare, Chalfont St Giles,
England) for affinity purification. The purity of TraK was
assessed by SDS–PAGE. Imidazole from the HisTrap affinity
purification was removed by buffer exchange during concen-
tration (Amicon tubes, 3000 MWCO; Merck, Darmstadt,
Germany).
Purified TraK protein with a concentration of 1 mg ml1
was subjected to buffer-optimization screening by differential
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scanning fluorimetry (Ericsson et al., 2006) using all crystal-
lization buffers present in the Index, PEG/Ion, MembFac
(Hampton Research, Aliso Viejo, California, USA) and
Morpheus (Molecular Dimensions, Newmarket, England)
screens. For the assay, 10 ml protein sample was mixed with
10 ml of the respective buffer and 5 ml 50 SYPRO Orange
(Sigma–Aldrich, St Louis, USA) stock. The resulting thermo-
stability curves were analyzed and a new extraction buffer was
designed by combining the buffer components (Collins et al.,
2004) which showed a thermostabilizing effect while keeping
the composition as simple as possible. The optimized TraK-
lysis buffer consisted of 50 mM HEPES pH 7.6, 200 mM
ammonium sulfate and was used for all subsequent TraK
extractions, as well as for crystallization.
2.2. Expression of the TraKD selenomethionine derivative
For the expression of selenomethionine-labelled (SeMet)
TraK protein, pQTEV-traK plasmid DNA was isolated
and transformed into the methionine-auxotroph E. coli strain
B834 (DE3) (Novagen, Merck, Darmstadt, Germany) using
standard protocols. The cells were resuspended in M9 minimal
medium at an OD600 of 0.6, grown for 1 h at 37C and
induced with 1 mM IPTG. At the same time, 25 mg seleno-
methionine was added and overexpression continued for 3 h.
The cells were harvested and immediately frozen at 20C.
SeMet TraK expression levels were monitored by SDS–
PAGE. Protein extraction was performed as described above.
2.3. Biophysical analysis of TraKD
TraK was extracted and His-affinity purified in 50 mM
Tris, 100 mM ammonium sulfate pH 7.45. TraK-containing
fractions were pooled and concentrated via centrifugation in
Amicon tubes (Millipore Amicon, 3000 MWCO). TraK was
further purified by size-exclusion chromatography using a
Superdex 200 HR 10/30 column (GE Healthcare, Chalfont St
Giles, England). A gel-filtration standard (670, 158, 44, 17 and
1.35 kDa; Bio-Rad, Hercules, California, USA) was used to
calculate the molecular weight of TraK. TraK-containing
fractions were stored at 80C for subsequent experiments.
Circular-dichroism (CD) measurements were performed on
a Jasco J715 (Jasco Instruments, Gross-Umstadt, Germany)
spectropolarimeter equipped with an external thermostat.
Spectra were measured from 260 to 190 nm in a 0.01 cm
cuvette at a protein concentration of 0.95 mg ml1. Ten indi-
vidual spectra were accumulated and the standard deviation
was calculated from the repeated measurements. Temperature
scans were performed in a 0.02 cm temperature-controlled
cuvette in the range from 25 to 95C using a step-scan
procedure with a constant wavelength of 208 nm. Spectra
resulting from three accumulated scans were measured every
5C. The temperature gradient was set to 1C per minute.
TraK was applied at a concentration of 0.46 mg ml1. The
CD data were evaluated using the DichroWeb online service
(Whitmore & Wallace, 2008) using reference database No. 4.
For the dynamic light-scattering (DLS) measurements, a
size-exclusion fraction containing 0.95 mg ml1 TraK was
measured directly in a 45 ml cuvette. Ten measurements with
constant baseline were merged and the monodispersity was
assessed.
For the SAXS measurements on the X33 beamline at
DESY, Hamburg, Germany, TraK was suspended in 100 mM
ammonium sulfate, 100 mM NaCl, 50 mM HEPES pH 7.0.
Size-exclusion purified protein was further concentrated and
TraK was measured at three different concentrations: 6.3,
3.0 and 1.64 mg ml1. The program PRIMUS (Konarev et al.,
2003) was applied to subtract the buffer from the protein data.
Maximum intensity (I0) and the radius of gyration (Rg) were
calculated from the Guinier plot generated from the data at
3.0 mg ml1. The I0 was used to calculate the molecular weight
of TraK in solution and GNOME (Svergun, 1992) was used
to generate the output file for subsequent ab initio modelling
with GASBOR (Svergun et al., 2001) and CRYSOL (Svergun
et al., 1995) to generate a scattering curve from the X-ray-
derived model. The BUNCH software (Petoukhov & Svergun,
2005) was applied to fit the X-ray data to the SAXS scattering
curve of TraK. This was carried out by ab initio and rigid-
body modelling of TraK and the N-terminal His tag of the
construct, which was present in solution but was disordered
and thus not visible in the X-ray model. The GASBOR-
derived model was converted to a volumetric model using
SITUS (Wriggers, 2010). CHIMERA (Pettersen et al., 2004)
was used to fit the TraK crystal structure to the converted
SAXS model.
2.4. Subcellular fractionation of E. faecalis JH2-2 (pIP501)
and immunolocalization of TraK
Subcellular fractionation of E. faecalis JH2-2 (pIP501) was
performed according to Buttaro et al. (2000) with modifica-
tions. An exponentially growing culture (OD600 = 0.5) of
E. faecalis JH2-2 (pIP501) was chilled on ice for 15 min,
washed twice with an equal volume of potassium phosphate
buffer (50 mM, pH 7.0) and resuspended [1:50(v/v)] in lysis
buffer (50 mM KH2PO4/K2HPO4 pH 7.0, 1 mM EDTA, 1 mM
MgCl2, 100 mg ml
1 DNase, 100 mg ml1 RNase). The cells
were broken by FastPrep-24 (MP Biomedicals, Illkirch,
France) using lysing matrix E (1.4 mm ceramic spheres,
0.1 mm silica spheres, 4 mm glass beads; MP Biomedicals,
Illkirch, France). Unlysed cells were removed by low-speed
centrifugation. The cell-wall fraction was then harvested by
high-speed centrifugation at 17 000g for 20 min at 4C, the
membrane fraction was obtained by ultracentrifugation of the
supernatant at 163 000g for 2 h at 4C (OTD Combi ultra-
centrifuge, Thermo Fisher Scientific GmbH, Dreieich,
Germany). The remaining supernatant contained the soluble
proteins. TraK was localized in the fractions (cell wall,
membrane and cytoplasm) by immunostaining with primary
polyclonal anti-TraK antibody and a secondary horseradish
peroxidase-conjugated anti-rabbit IgG antibody (Promega
GmbH, Mannheim, Germany). Polyclonal anti-TraK anti-
bodies were derived from BioGenes (Berlin, Germany)
according to the manufacturer’s standard immunization
protocol for rabbit. The rabbit anti-TraK were subsequently
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purified by antigen affinity chromatography according to the
manufacturer’s protocol.
2.5. TraK start-codon mutation
In order to evaluate whether the TraK double bands arise
from proteolytic digestion or the utilization of a second
putative ribosomal binding site (RBS) and subsequent start
codon, the full open reading frame (ORF) of traK including its
RBS was cloned into the pQTEV expression vector. We next
constructed a double mutant comprising pQTEV and traK
start-codon mutations (the respective ATG codon was
changed to ACG) using the QuikChange Site-Directed
Mutagenesis Kit (Agilent Technologies, Santa Clara, Cali-
fornia, USA).
The constructs were transformed into E. coli BL21-
CodonPlus(DE3)-RIL competent cells, which were grown
in LB medium supplemented with 100 mg ml1 ampicillin.
Expression was induced at an OD600 of 0.6 with 0.5 mM IPTG
at 37C. The cells were harvested 3 h after induction and
samples were loaded onto a 12% SDS polyacrylamide gel
and subjected to Western blotting with rabbit polyclonal anti-
TraK antibodies followed by a secondary horseradish
peroxidase-conjugated anti-rabbit IgG antibody (Promega,
Mannheim, Germany).
2.6. Protease protection assay
E. faecalis JH2-2 (pIP501) was grown in 50 ml Todd Hewitt
Broth medium (THB) supplemented with 20 mg ml1 chlor-
amphenicol and 2%(w/v) glycine to an OD650 of 0.4. Cells
were chilled on ice for 15 min, harvested by centrifugation
at 4000g for 10 min at 10C and resuspended in 10 ml PBS
supplemented with 10 mg ml1 BSA, 1 mg ml1 lysozyme and
10 U mutanolysin. E. faecalis JH2-2 (pIP501) peptidoglycan
was digested for 90 min at 37C and protoplast formation was
confirmed by light and phase-contrast microscopy. In order to
evaluate the survival rate of the cells, serial dilutions (103–
106) of 10 ml cell suspension were plated onto modified THB
agar plates [THB, 0.5 M sodium succinate, 20 mg ml1 chlor-
amphenicol, 0.8%(w/v) agarose] before and after peptido-
glycan digestion. Protoplasts were harvested by
centrifugation, washed three times in PBS and 1 mg ml1 BSA
and resuspended in THB medium without antibiotics. Protein
digestion was induced by adding varying concentrations of
proteinase K (0.1–10 mg ml1) to a 1 ml cell suspension. 100 ml
samples were withdrawn after 5 min at 37C and PMSF was
added to a final concentration of 1 mM. Protoplasts were
harvested by centrifugation as described above, resuspended
in up to 30 ml SDS–PAGE sample buffer, denatured and
loaded onto an 18% SDS polyacrylamide gel.
To confirm that protection from degradation of the cyto-
plasmic control protein TraN is owing to the lipid bilayer in
the cytoplasmic membrane, Triton X-100 (Roth, Karlsruhe,
Germany) was added to a sample containing 5 mg ml1
proteinase K to a final concentration of 1%(v/v) and protein
digestion continued for 5 min. 1 mM PMSF was added to stop
the reaction and 10 ml cell suspension was mixed with 10 ml
SDS–PAGE sample buffer.
Samples were loaded onto an 18% SDS polyacrylamide gel
and subjected to Western blotting. Blots were probed with
rabbit polyclonal anti-TraK and anti-TraN antibodies
(BioGenes, Berlin, Germany) followed by a secondary
horseradish peroxidase-conjugated anti-rabbit IgG antibody
(Promega, Mannheim, Germany).
2.7. Opsonophagocytosis killing assay (OPA)
The opsonophagocytic assay was performed as described
previously (Theilacker et al., 2012; Goessweiner-Mohr,
Grumet, Arends et al., 2013). In case of the OPAs including
pre-incubation with peptidoglycan-degrading enzymes, a cell-
wall enzymatic digestion was performed by co-incubating
harvested E. faecalis JH2-2 cells harbouring tpIP501
(OD650 nm = 0.4) with 0.1 mg ml
1 lysozyme and 0.01 mg ml1
mutanolysin at 37C for 15 min. After enzymatic treatment,
the samples were washed with TSB medium, readjusted to an
OD650 nm of 0.4 and utilized in the subsequent experiments.
2.8. Crystallization and crystal optimization
Crystallization trials for His-tagged TraK were initially set
up with Index screen at a stock concentration of 5.5 mg ml1
using the microbatch method (Chayen et al., 1992). After
evaluation of the first plate, the following screens were
prepared at different concentrations: Index, Crystal Screen,
Crystal Screen 2, MembFac, PEG/Ion (Hampton Research),
JCSG and Morpheus (Molecular Dimensions). The drop ratio
was 1:1 with a total drop volume of 1 ml. All plates were
covered with paraffin oil (a total of 4 ml) and stored at 20C.
The formation of crystals was monitored over several weeks.
Potential protein crystals were tested for diffraction using
a rotating-anode diffractometer (MicroStar; Bruker AXS,
Madison, Wisconsin, USA). The most promising of several
positive conditions, Morpheus conditions 52 (0.03 M each of
diethylene, triethylene, tetraethylene and pentaethylene
glycols, 0.05 M each of imidazole and MES pH 6.5, 12.5% each
of MPD, PEG 1K and PEG 3350) and 85 (0.02 M each of
sodium l-glutamate, alanine, glycine, lysine–HCl and serine,
0.05 M each of imidazole and MES pH 6.5, 15% each of
PEG MME 550 and PEG 20K) were selected for microbatch
precipitant/protein concentration optimization matrices. A
constant protein drop volume of 1 ml and different protein
stock concentrations were used.
The original conditions showed small, compact crystals with
poor diffraction (about 7 A˚), which appeared after only a few
days. The optimization did not improve the crystal diffraction
limit or quality, but the use of the enhanced extraction buffer
TraK-lysis led to the formation of larger crystals with
improved diffraction behaviour. Optimized conditions were
used for the following setup with selenomethionine-containing
TraK. Crystals were harvested from condition 52 of the
Morpheus screen (protein stock concentration 12.9 mg ml1).
Native crystals were taken from condition 85 of the Morpheus
screen (protein stock concentration 14.14 mg ml1).
research papers
Acta Cryst. (2014). D70, 1124–1135 Goessweiner-Mohr et al.  TraK 1127
2.9. Data collection and processing
Data collection was performed at 100 K on the synchrotron
beamline X06DA at SLS, Villigen, Switzerland. No cryopro-
tectant was needed to preserve the crystals. The data sets were
processed and scaled together using iMosflm (Battye et al.,
2011) and SCALA (Evans, 2006). AutoSol (McCoy et al., 2007;
Terwilliger et al., 2009) and AutoBuild (Terwilliger et al., 2008)
from the PHENIX software suite (Adams et al., 2010) were
used to define the selenium heavy-atom sites using a selenium-
derivative MAD data set (peak, inflection and high-end
remote), as well as to build an initial model. The resulting
model was completed manually in Coot (Emsley et al., 2010),
refined with REFMAC5 (Murshudov et al., 2011) and utilized
as a template for molecular replacement with AutoMR
(McCoy et al., 2007) from the PHENIX software suite, using
a native data set of higher diffraction quality. The resulting
model was again completed manually in Coot and refined with
REFMAC5. The refined X-ray model was validated with the
online service MolProbity (Chen et al., 2010). The secondary-
structure elements were determined using STRIDE (Heinig &
Frishman, 2004). The structural alignment of TraK internal
monomers was conducted with MASS (Dror et al., 2003). The
DALI (Holm & Rosenstro¨m, 2010) and MATRAS (Kawabata,
2003) online structural alignment servers were utilized to
search for structural homologues of TraK. PyMOL (v.1.3;
Schro¨dinger) was used to prepare structure representations, to
calculate the r.m.s.d. of the TraKmonomer alignment and to
generate the surface representation of the TraK electrostatic
potential.
2.10. Mass spectrometry of TraKD crystals
Several crystals of TraK were dissolved in 10 ml pure
H2O and investigated by MALDI–TOF mass-spectrometric
analysis (ultrafleXtreme; Bruker, Vienna, Austria).
2.11. Sequence-based comparison and characterization
The following online services were used to search for
transmembrane motifs in the TraK sequence and potential
homologous proteins: HMMTOP (Tusna´dy & Simon, 2001),
MemsatSVM (Nugent & Jones, 2009) and Memsat3 (Jones et
al., 1994).
PSIpred (Jones, 1999) was used to predict the secondary-
structure content of TraK and of structurally related proteins,
but where known the secondary structure was derived from
the crystal structure. General features of the His-tagged TraK
construct were assessed with ProtParam (Gasteiger et al.,
2003).
3. Results
3.1. TraK localizes to the Enterococcus cell envelope
To localize the TraK protein in vivo, an exponentially
growing culture of E. faecalis JH2-2 (pIP501) was fractionated
into cell-wall, membrane and cytoplasmic fractions as
described by Buttaro et al. (2000). TraK was always visualized
as a doublet and was mainly found in the cell-envelope frac-
tions (cell wall and membrane; Fig. 1a), with only a weak
signal in the cytoplasmic fraction. The TraN protein predicted
by PSORTb to localize to the cytoplasm, which was analyzed
in parallel in the same experiment, was exclusively found in
the cytoplasmic fraction, consistent with a sound separation of
cytoplasmic and cell-envelope proteins (Arends et al., 2013).
A possible explanation for the second signal could be a
second start codon with its own ribosomal binding site within
the traK coding region. As the second gene product was also
detected in the cell-envelope fractions, the N-terminal trans-
membrane motif needs to be present. A start codon at
nucleotide position 3923 (GenBank AJ5058232) has an
adequate distance to a ribosomal binding site at positions
3908–3912. The mass difference for the larger TraK protein
(start codon at nucleotide position 3818) and the gene product
starting at position 3923 accounts for 4.1 kDa and is in good
agreement with the difference between the two signals on the
gel. To evaluate whether the TraK double bands arise from
proteolytic digestion or utilization of the second putative
ribosomal binding site and the subsequent start codon, we
constructed a mutant comprising a mutation in the first TraK
start codon and utilized immunodetection to monitor the TraK
expression profile. The experiment confirmed that the second
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Figure 1
TraK localization and functional characterization. (a) TraK localizes to
the cell envelope of E. faecalis JH2-2 cells harbouring pIP501. The
localization of TraK in the cell fractions was detected by Western blot
with polyclonal anti-TraK antibodies. CW, cell wall; M, membrane; CP,
cytoplasm. (b) Opsonophagocytic killing assay using anti-TraK anti-
bodies, as well as anti-TraM antibodies as a positive control.
start codon is indeed being used (Supplementary Fig. S1a)1,
thus it is likely that expression of the traK gene leads to two
gene products in vivo.
In order to unambiguously determine the orientation of the
TraK protein in the E. faecalis membrane, we performed a
protease protection assay. To this end, we generated proto-
plasts from native E. faecalis JH2-2 (pIP501) cells from which
the peptidoglycan layer had been removed by lysozyme and
mutanolysin treatment. As Supplementary Fig. S1(b) shows,
TraK is proteolytically digested depending on the protease
concentration, indicating that the C-terminal domain of TraK
is positioned outside the cytoplasmic membrane. In contrast,
the cytoplasmic T4SS component TraNpIP501 is not digested
by the protease, as it is obviously shielded by the intact
cytoplasmic membrane of the E. faecalis protoplasts and is
only degraded when the protoplasts are solubilized by Triton
X-100 treatment (Supplementary Fig. S1c).
The opsonophagocytic killing assay showed no killing of
E. faecalis JH2-2 (pIP501) cells with polyclonal antibodies
raised against TraK at dilutions of 1:10, 1:50 (Fig. 1b) and
1:100 (data not shown), in contrast to the positive control with
anti-TraM antibodies. We conclude that while the protein
localizes to the bacterial cell envelope and faces the cell
exterior, it is not surface-exposed. To evaluate whether the
thick peptidoglycan layer of the E. faecalis cells was respon-
sible for sterically preventing the anti-TraK antibodies from
binding to the protein, we conducted OPA experiments
including pre-incubation of the E. faecalis cells with varying
concentrations of peptidoglycan-degrading enzymes (lyso-
zyme and mutanolysin). None of these setups resulted in
increased killing of E. faecalis cells harbouring the pIP501
plasmid (D. Laverde-Gomez, T. Sakinc & E. Grohmann,
unpublished data), thus surface accessibility of TraK is likely
to be prevented by a different mechanism.
3.2. TraKD is a monomeric protein
Attempts to overexpress and purify full-length TraK
(34.7 kDa) failed owing to solubility problems. Consequently,
a stable truncation derivative, TraK (30.6 kDa), was
constructed and purified. It lacks the N-terminal putative
transmembrane domain, but possesses an N-terminal 7His
tag. TraK eluted from the gel-filtration column as a single
peak (Supplementary Fig. S2a), indicative of a homogeneous
species with an apparent molecular weight of 44.9 kDa. This
value compares with the theoretical molecular weight of the
His-tagged construct of 30.6 kDa, suggesting that TraK is a
monomer in solution.
The monodispersity of TraK was evaluated by DLS. Ten
measurements with constant baseline were merged, yielding
a single peak with a calculated polydispersity of 13.2% and a
hydrodynamic radius (Rh) of 3.6 nm (Supplementary Fig. S2a).
Purified TraK is folded in solution and has a mixed
/ composition (Supplementary Fig. S3a). The amount of
-helices (29%) exceeds that of -sheets (20%) (Supple-
mentary Fig. S3b). The large proportion of unordered struc-
ture (31%) may result from flexible N-terminal or C-terminal
parts. Temperature scans revealed that TraK undergoes a
transition at 75C (Supplementary Fig. S3c), reaches a plateau
at 95C and is trapped in this state (i.e. no refolding during the
down-scan).
In order to determine the oligomeric state and shape of
TraK in solution, SAXS measurements were performed. The
measurements yielded an I0 of 27.24, a radius of gyration (Rg)
of 2.97 nm and a Dmax of 10 nm, as calculated from the Guinier
plot (data at 3.0 mg ml1) and the p(r) function, respectively.
From the I0, we calculated the apparent molecular weight of
TraK in solution using BSA as a molecular-weight standard
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Table 1
Data-collection and processing statistics of scaled data.
Values in parentheses are for the highest resolution shell.
Se derivative Native
Data sets MAD peak MAD inflection point MAD high-end remote
Used for molecular replacement
and structure refinement
Beamline X06DA (PXIII), SLS,
Villigen, Switzerland
X06DA (PXIII), SLS,
Villigen, Switzerland
X06DA (PXIII), SLS,
Villigen, Switzerland
X06DA (PXIII), SLS,
Villigen, Switzerland
Space group I4 I4 I4 I4
Detector MAR CCD MAR CCD MAR CCD MAR CCD
Unit-cell parameters (A˚, ) a = b = 113.59, c = 120.84,
 =  =  = 90.00
a = b = 113.83, c = 121.05,
 =  =  = 90.00
a = b = 113.92, c = 121.13,
 =  =  = 90.00
a = b = 114.04, c = 120.52,
 =  =  = 90.00
Wavelength (A˚) 0.9792 0.9797 0.9715 1.0
Resolution range (A˚) 46.83–3.50 (3.69–3.50) 41.46–3.50 (3.69–3.50) 41.49–3.50 (3.69–3.50) 41.42–3.00 (3.16–3.00)
Rmeas (%) 0.127 (0.455) 0.112 (0.434) 0.122 (0.500) 0.036 (0.323)
hI/(I)i 15.4 (5.8) 18.8 (6.8) 17.43 (6.0) 12.3 (2.3)
No. of molecules in asymmetric unit 2 2 2 2
Matthews coefficient (A˚3 Da1) 3.18 3.20
Solvent content (%) 61.40 61.60
Measured reflections 122640 (17925) 146350 (21439) 146164 (21317) 117365 (16933)
Unique reflections 9733 (1416) 9802 (1432) 9824 (1428) 15465 (2231)
Multiplicity 12.6 (12.7) 14.9 (15.0) 14.9 (14.9) 7.6 (7.6)
Completeness (%) 99.9 (100) 99.9 (100) 99.9 (100) 99.9 (100)
1 Supporting information has been deposited in the IUCr electronic archive
(Reference: MN5045).
(Pavkov et al., 2008). The value of 28.1 kDa is in good
agreement with the theoretical molecular weight of TraK
(30.6 kDa). Calculating ab initio models from the scattering
function, we observed an elongated particle, which may be
owing to the flexible N-terminal end of TraK including the
unstructured 7His tag.
3.3. X-ray data collection
Owing to the lack of structures with significant sequence
similarity to TraK, selenomethionine-containing TraK
crystals were used for structure solution by multiwavelength
anomalous dispersion (MAD). A single selenomethionine-
containing crystal showed a non-twinned pattern and
diffracted to 3.5 A˚ resolution at the synchrotron. We
performed a fluorescence scan to validate the presence of
selenomethionine in the crystal and to define the optimal
setup for anomalous data collection at the Se K absorption
edge. A full MAD data set was collected at the peak
(0.9792 A˚), inflection (0.9797 A˚) and high-end remote
(0.9715 A˚) wavelengths. A crystal-to-detector distance of
330 mm, an oscillation range of 1.0 and an exposure time of
1 s per image were chosen. 360 frames were taken at each of
the three wavelengths.
The selenomethionine-derivative crystal belonged to space
group I4, with unit-cell parameters a = 113.59, b = 113.59,
c = 120.84 A˚,  =  =  = 90.00 and two molecules per
asymmetric unit. Tables 1 and 2 provide an overview of the
data-collection and refinement statistics. The Matthews coef-
ficient (Matthews, 1968) was calculated as 3.18 A˚3 Da1, with
a solvent content of 61.4%. The MAD data yielded a preli-
minary model of TraK, which was used as a template for
molecular replacement with native data to 3.0 A˚ resolution. A
data set of 360 frames was collected at a wavelength of 1 A˚,
with a crystal-to-detector distance of 320 mm, an oscillation
range of 0.5 and an exposure time of 1 s per image. The native
crystal was found to be isomorphous to the selenomethionine-
derivative crystal, belonging to the same space group (I4) and
with nearly identical unit-cell parameters (a = 114.04,
b = 114.04, c= 120.52 A˚,  =  =  = 90.00) and two molecules
per asymmetric unit (Table 1).
To confirm the integrity of TraK in the crystals, we
analyzed dissolved crystals via MALDI–TOF mass spectro-
metry (MS). The MS analysis showed that the TraK crystals
contained the full-length protein (Fig. 2). The N-terminal ends
of the monomers, namely the 28-residue His tag and TraK
residues 66–102, appeared to be flexible and were not
observed in the electron-density maps. Supplementary Fig. S4
provides an overview of the full-length TraK protein, the
TraK construct, the predicted and the actual secondary-
structure contents and the amino-acid sequence found in the
TraK crystals. The final coordinates and structure-factor
amplitudes have been deposited in the PDB as entry 4hic.
3.4. The TraKD crystal structure
The crystal structure of TraK represents a novel fold, as
there were no significantly structurally related proteins found
in the PDB as determined by DALI and MATRAS (Supple-
mentary Table S1). TraK comprises a mixed / fold with
seven -helices (h1–h7) and nine -strands (s1–s9) (Fig. 3a).
Two antiparallel -sheets (A, s1–s5; B, s6–s9) are located in
the central parts of the protein and are mostly protected from
solvent contacts by -helices and loop regions. Two of the
helices (h4 and h5) are positioned in a parallel manner,
dominating one side of the molecule. The curved -sheet B is
wrapped around a long -helix (h2), which is stabilized on the
surface of the protein solely through hydrophobic interactions.
These interactions occur between the side chains of the helix 2
residues, which face towards the centre of the protein (Ala116,
Ala119, Ala122, Phe123 and Trp126), and the side chains of
the residues of -strands 6–9 (Phe234, Trp236, Ile267, Met288,
Trp297 and Val299), which are displayed on the concave
surface of -sheet B (Fig. 3b). The topology of the TraK
crystal structure is depicted in Fig. 3(c). The structure
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Table 2
Processing statistics of refined data.
Resolution (A˚) 40.32–3.00
No. of reflections 15465
Rwork/Rfree 0.2050/0.2337
No. of atoms
Protein 3310
Water 0
B factors (A˚2)
Protein 59.79
Water —
R.m.s. deviations
Bond lengths (A˚) 0.011
Bond angles () 1.577
Ramachandran outliers 6 (of 404)
Rotamer outliers 18 (of 366)
Ramachandran favoured (%) 94.06
MolProbity score 2.84 (84th percentile)
Figure 2
MALDI–TOF analysis of TraK crystals. TraK crystallized as a full-
length His-tagged construct (30.6 kDa).
harbours a surface area of 10 597 A˚2. When analyzing the
surface electrostatic potential (Fig. 3d), we observed a mainly
positively charged upper half of the protein (h3 and the loop
region between s4 and s5) and a positively charged area in the
middle of the protein (the unordered region between h7 and
s7), as well as large negatively charged areas in the middle (s6
and the loop region between s7 and s8; the C-terminal residues
and h6) and among the lower half of the protein (h2 near the
N-terminus). The high degree of surface-exposed charged
residues explains the high solubility of the protein which was
observed during purification. The alignment of the two TraK
monomers showed an r.m.s.d. value of 0.33 A˚, suggesting only
minor structural differences.
3.5. The TraKD crystal structure fits to the SAXS solution data
The crystal structure was compared with the low-resolution
solution structure by generating a theoretical SAXS curve
from the refined coordinates using CRYSOL. The resulting
curve showed significant differences from the experimental
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Figure 3
The structure of TraK103–306. (a) Cartoon representation of TraK with views onto the two parallel helices (h4 and h5) and rotated by 180
 around the
vertical axis; secondary-structure elements are highlighted (helices in cyan, strands in purple) and numbered. (b) Detailed view of the residues involved
in the hydrophobic interaction between helix 2 and the antiparallel -sheet B. (c) Topology representation of the TraK fold. (d) Surface representation
of the electrostatic potential of TraK; front view and rotated by 180; red, negative charge; blue, positive charge; the C-terminal and N-terminal ends of
the protein are indicated.
observations (Fig. 4a). As the 7His tag and TraK residues
66–102 were not assigned in the electron-density map, the
refined TraK103–306 structure was significantly smaller than
the original construct. To take these differences in protein size
into account, we used the program BUNCH to generate the
missing N-terminal region by ab initio modelling and iterative
fitting of the resulting model to the experimental data (Fig. 4a).
50 ab initio models were generated with GASBOR and aver-
aged. To compare the size of the crystal structure with the
SAXS-derived model of TraK, we fitted the crystal structure
to the SAXS model. Although the averaged SAXS model
appears to be much more elongated than the crystal structure,
TraK103–306 fits very well into the main density (Fig. 4b).
The N-terminal end of the crystal structure faces towards the
empty tail. We conclude that the non-visible N-terminal resi-
dues of the TraK construct are responsible for the elongated
shape of the SAXS model.
3.6. TraK-like proteins were exclusively detected in
Enterococcus and Streptococcus T4SSs
We performed an extended search for TraK-like proteins in
a broad spectrum of conjugative plasmids, transposons, inte-
grative conjugative elements (ICEs) and genetic islands from
G and G+ bacteria. The candidates were sorted according
to their similarity to the template structure (TraK) based on
secondary-structure prediction. The results of the prediction-
based comparison and sequence alignments of potential TraK-
like proteins can be found in detail in Supplementary Figs. S5
and S6. All of the analyzed proteins showing a TraK-like
secondary-structure composition belonged to T4SSs of G+
origin (five plasmids and three ICEs). Except for one protein
from S. pyogenes plasmid pSM19035, all candidate T4SS
proteins were found in Enterococcus species. With the
exception of protein P49 from E. faecium conjugative plasmid
pVEF3 (261 amino acids), which lacks about 45 amino acids at
its N-terminal end, all other TraK-like proteins have a length
of approximately 300 residues and a small N-terminal -helical
domain, which is predicted to be cytoplasmic. Interestingly, in
the case of the E. faecalis plasmid pRE25 (Schwarz et al., 2001)
two putative T4SS proteins exhibit high sequence identity to
TraK, with ORF34 representing the N-terminal part and
ORF35 the C-terminal part of TraK. It appears that the two
ORFs have been generated from a single ancestor gene by a
frame-shift mutation (Grohmann et al., 2003), as the length
and secondary-structure composition of TraK can be recon-
structed by merging the amino-acid sequences of T4SS
proteins ORF34 and ORF35.
4. Discussion
Prokaryotic genome plasticity is greatly increased by conju-
gative plasmid transfer. Consequently, the conjugative spread
of antibiotic-resistance and virulence genes among pathogens
and commensal bacteria has an enormous impact on human
healthcare (Zechner et al., 2012). Over the last decades, an
increasing interest in the field of bacterial conjugation can be
observed.
The T-DNA transfer system from A. tumefaciens is the
prototype T4SS. It is the best-investigated model system and
has been studied since the late 1970s (Gurley et al., 1979).
A. tumefaciens uses a T4SS to inject tumour-inducing factors
into plant cells, a process that involves the transport of
proteins and plasmid DNA alike (Cascales & Christie, 2003;
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Figure 4
Comparison of the TraK SAXS data and the crystal structure. (a) The calculated SAXS curve (dashed black line) from the TraKX-ray structure does
not match the experimental SAXS data (grey line); ab initio modelling of the missing N-terminal region of the TraM construct allows a significantly
improved fit of the data (black line). (b) Superposition of the TraK crystal structure with the GASBOR-derived SAXS model; 50 ab initio GASBOR
models were averaged but not filtered.
Nagai & Roy, 2003; Backert & Meyer, 2006). In the last 15
years, more and more T4SSs of G origin have been studied,
leading to a substantial amount of biophysical, functional and
structural information. Among the solved protein structures
are the VirD4 homologue TrwB from E. coli plasmid R388
(Gomis-Ru¨th et al., 2001) and the VirB5 homologue TraC
from E. coli plasmid pKM101 (Yeo et al., 2003), as well as
VirB11 from Brucella suis (Hare et al., 2006) and VirB11 from
the Cag pathogenicity island of Helicobacter pylori (Yeo et al.,
2003). Other examples are the VirB8 proteins from A. tume-
faciens (Bailey et al., 2006) and B. suis (Terradot et al., 2005).
Beside these individual proteins, the structure elucidation of
the core complex of the pKM101 T4SS from E. coli consid-
erably contributed to the knowledge base of G T4S
(Chandran et al., 2009; Fronzes et al., 2009). The combination
of electron microscopic and crystallographic methods
provided a detailed view of the assembly and partial archi-
tecture of the conjugative transfer apparatus.
Equal advances have not yet been achieved for systems
originating from G+ bacteria. However, it is promising to see
the amount of structural information on G+ T4SSs grow over
recent years. In early 2012, the high-resolution structure of the
VirB8-like transfer protein TcpC from C. perfringens plasmid
pCW3 (Porter et al., 2012) became available, shortly followed
by the structure of VirB4 from Thermoanaerobacter pseud-
ethanolicus (Wallde´n et al., 2012). In late 2012, Goessweiner-
Mohr and coworkers published the VirB8-like structure of the
TraM C-terminal domain, the first transfer protein structure
solved from the pIP501-encoded enterococcal T4SS (Goess-
weiner-Mohr, Grumet, Arends et al., 2013). As the cell-wall
structures of G and G+ bacteria differ significantly , reflected
by the vastly different makeup of G+ T4SSs, the major
components of the conjugative core complex have not yet
been identified in G+ T4SSs. Thus, the molecular mechanisms
of DNA transfer in G+ bacteria remain largely unknown.
Many important human pathogens, such as enterococci,
streptococci and staphylococci, belong to this group of
prokaryotes. Hence, the lack of knowledge about G+ T4S is
particularly concerning (Burns, 2003).
In this study, structural and biophysical approaches were
used to characterize TraK, a putative T4SS protein from the
E. faecalis conjugative model plasmid pIP501. This task was
especially demanding, as no sequence similarities of TraK to
T4SS components of G origin have been detected. We
showed that TraK is a cell envelope-located protein (Fig. 1a)
with its C-terminal domain facing the cell exterior (Supple-
mentary Fig. S1b). However, antibodies directed against
TraK were not able to recruit macrophages to pIP501-
harbouring E. faecalis cells. We conclude that although TraK is
located in the bacterial cell envelope, it is not surface-exposed,
in contrast to the previously reported pIP501 T4SS protein
TraM (Goessweiner-Mohr, Grumet, Arends et al., 2013). A
possible explanation for these findings is that TraK might not
be positioned near the opening in the peptidoglycan layer
locally generated by the pIP501-encoded muramidase TraG
for the assembly of the conjugative T4SS core complex
(Arends et al., 2013). In this scenario, the anti-TraK anti-
bodies would not be able to access the protein surface and
thus would not be able to recruit macrophages to the
E. faecalis cells. As OPAs including peptidoglycan-degrading
enzymes were negative, we conclude that the surface acces-
sibility of TraK is likely to be prevented by a different
mechanism. A role as an exclusion factor or its involvement in
cell-to-cell attachment, as suggested for the E. faecalis pCF10-
encoded PrgA and PrgB (Alvarez-Martinez & Christie, 2009),
is unlikely, since these tasks would clearly require a surface-
exposed location.
A second explanation would be that TraK might be an
integral component of the core complex. In the case of the
pKM101 core complex, three proteins homologous to VirB7,
VirB9 and VirB10 are part of the 172 A˚ diameter ring-shaped
structure (Fronzes et al., 2009; Rivera-Calzada et al., 2013).
One of the components, VirB9, is covered by the elongated
molecule VirB7, which substantially limits its accessible
surface area. Similarly, as yet undetected interactions of TraK
with other components of the putative pIP501 core complex
might also restrict its accessible surface and could potentially
exclude stable binding of the antibodies to their respective
surface epitopes. Previous studies using yeast two-hybrid and
pull-down assays have not shown any interactions of TraK
with other pIP501 T4SS components (Abajy et al., 2007).
Nonetheless, the elucidation of the pKM101 core complex
buildup, i.e. the interaction of its components, was only made
possible by their co-expression (Fronzes et al., 2009; Rivera-
Calzada et al., 2013). We expect a similar behaviour for the
pIP501 core complex proteins; co-expression tests have
recently been started.
It is surprising that TraK only shows a very limited number
of structural relatives. Furthermore, only some of the known
enterococcal T4SSs encode a putative transfer protein with
a TraK-like secondary-structure composition, e.g. the well
characterized enterococcal T4SS encoded by the conjugative
plasmid pCF10 lacks a corresponding gene product (Bhatty
et al., 2013). This suggests an exclusive role for TraK-like
proteins in the respective T4SSs, in contrast to the prevalence
of the major T4SS proteins: relaxases (Kopec et al., 2005;
Garcilla´n-Barcia et al., 2009; Lang et al., 2010), coupling
proteins (Llosa et al., 2003; Gomis-Ru¨th et al., 2004; Parsons
et al., 2007), transglycosylases (Koraimann, 2003; Zahrl et al.,
2005; Bantwal et al., 2012; Arends et al., 2013) and ATPases
(Savvides, 2007), as well as VirB8-like proteins (Baron, 2006;
Porter et al., 2012; Goessweiner-Mohr, Grumet, Arends et al.,
2013). One explanation for the exclusive distribution of TraK-
like proteins might be the specific host range of the T4SS.
pIP501, as well as pRE25, owing to their nearly identical
buildup (Schwarz et al., 2001), exhibit a particular broad host
range, with pIP501 even able to transfer and stably replicate in
bacteria of G origin (Kurenbach et al., 2003).
We suggest that the TraK-like proteins might play an
important role in the adaptation of their respective T4SSs to
new hosts. Most likely, this adaptation involves adjustment
to the distinct cell-envelope compositions (Vollmer &
Seligman, 2010) of the various types of G+ bacteria. Inter-
estingly, close homologues of the pIP501 T4SS protein TraN
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were only found in the same range of enterococcal and
streptococcal T4SSs (N. Goessweiner-Mohr & W. Keller,
unpublished data), which suggests a connected function for
the two proteins.
Despite the growing structural and functional information
on T4SSs in general, further efforts are needed to identify the
function of TraK-like proteins, as well as to reveal the
components of the G+ T4SS core complex. Nevertheless, we
are confident that the structural elucidation of TraK will prove
to be a keystone in the growing understanding of T4S, as well
as in deciphering the structural differences and adaptations in
T4SSs among G+ bacteria.
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